help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clore, J. N.
Right arrow Articles by Watlington, C. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clore, J. N.
Right arrow Articles by Watlington, C. O.

Journal of Clinical Endocrinology & Metabolism, Vol 67, 824-831, Copyright © 1988 by Endocrine Society

ARTICLES

Adrenocorticotropin and cortisol-induced changes in urinary sodium and potassium excretion in man: effects of spironolactone and RU486

JN Clore, H Estep, H Ross-Clunis and CO Watlington
Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.

The role of the glucocorticoid (type II) receptor in the Na+ retention induced by cortisol is not known. The relative contribution of mineralocorticoid (type I) and type II receptor activation to changes in urinary Na+ and K+ excretion in man was studied using spironolactone and RU486 to inhibit type I and II receptors, respectively. Normal men eating a constant daily diet received either ACTH or cortisol for 5 days. Spironolactone (400 mg/day) inhibited ACTH (80 U/day)-induced kaliuresis, but not the Na+ retention produced by ACTH or cortisol (240 mg/day) and only blunted the modest Na+ retention induced by cortisol (120 mg/day). RU486 (1200 mg/day for the first 2 day) inhibited the first day kaliuresis and carbohydrate intolerance produced by cortisol, but did not affect the Na+ retention. Thus, the kaliuresis produced by cortisol and ACTH can be attributed to type II and type I receptor activation, respectively. The failure of RU486 to inhibit the Na+ retention induced by cortisol with evidence of adequate blockade of type II receptors indicates that the Na+ retention produced by cortisol is not mediated by type II receptor activation, but is, at least in part, mediated by the type I receptor.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. J. Rickard, J. W. Funder, J. Morgan, P. J. Fuller, and M. J. Young
Does Glucocorticoid Receptor Blockade Exacerbate Tissue Damage after Mineralocorticoid/Salt Administration?
Endocrinology, October 1, 2007; 148(10): 4829 - 4835.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. J. Rickard, J. W. Funder, P. J. Fuller, and M. J. Young
The Role of the Glucocorticoid Receptor in Mineralocorticoid/Salt-Mediated Cardiac Fibrosis
Endocrinology, December 1, 2006; 147(12): 5901 - 5906.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. A. Whitworth, G. J. Mangos, and J. J. Kelly
Cushing, Cortisol, and Cardiovascular Disease
Hypertension, November 1, 2000; 36(5): 912 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
N. L. Nakhoul, K. S. Hering-Smith, C. T. Gambala, and L. L. Hamm
Regulation of sodium transport in M-1 cells
Am J Physiol Renal Physiol, December 1, 1998; 275(6): F998 - F1007.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society